Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·-0.3%·₹1,351.95
Key Event9th AGM held on September 25, 2026 via video conference.
Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·+0.86%·₹1,356
Key EventTrading window closure announced for directors and promoters
ImpactShareholders must avoid trading during the closed window to prevent insider trading violations.Sign up to read impact
Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·-0.81%·₹1,379.75
Key EventCompany clarifies volume movement as normal market activity
ImpactThis confirms no hidden risks or upcoming changes, supporting confidence in transparent operations.Sign up to read impact
Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·-3.18%·₹1,420.75
Key EventUSFDA completes inspection of subsidiary facility with no GMP observations
Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·-1.76%·₹1,462.6
Key EventSenores Pharmaceuticals filed its FY 2025-26 annual report with BSE, highlighting financial growth and strategic acquisitions.
ImpactSenores is strengthening its position in high-growth regulated markets through strategic acquisitions and operational scaling, supported by robust financial growth and compliance.Sign up to read impact
Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·-0.37%·₹1,427.1
Key EventAGM approved Independent Director appointment, ESOP 2026, and director remuneration revisions
ImpactThe company is aggressively expanding in regulated markets and USFDA-approved manufacturing, with strong growth in key segments and strategic acquisitions driving future profitability.Sign up to read impact
Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·-0.37%·₹1,427.1
Key EventSenores Pharmaceuticals reported FY2025-26 revenue of ₹663 Cr, 62% YoY growth, with 51 approved ANDAs and expansion into US federal supply chains via Amerisyn and Zoraya.
ImpactSenores Pharmaceuticals is aggressively scaling its regulated and emerging market presence through strategic acquisitions, capacity expansion, and pipeline development, positioning for sustained growth with improving profitability targets and strengthened US market access.Sign up to read impact
Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·-0.37%·₹1,427.1
Key EventSenores Pharmaceuticals filed its BRSR report with BSE and NSE for FY 2025-26 on September 3, 2026.
ImpactThe company demonstrates strong governance and compliance, with no regulatory penalties and full female employee awareness coverage, supporting stable long-term operations.Sign up to read impact
Senores Pharmaceuticals Ltd (SENORES)
·Next Day Close·+0.67%·₹1,482.35
Key EventCompany schedules investor conference with Elara Capital
Senores Pharmaceuticals Limited (SENORES)
·Next Day Close·-1.57%·₹1,472.5
Key EventBoard approves new CS, independent director, ESOP scheme, and Mexico/Canada subsidiary plans
ImpactThese appointments and expansion plans signal leadership strengthening and international growth ambitions, potentially enhancing long-term value but requiring shareholder approval for ESOP and subsidiaries.Sign up to read impact